- Home
- BFRG vs BIAF Comparison
BFRG vs BIAF Comparison
Compare BFRG & BIAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BFRG
- BIAF
- Stock Information
- Founded
- BFRG 2017
- BIAF 2014
- Country
- BFRG United States
- BIAF United States
- Employees
- BFRG N/A
- BIAF N/A
- Industry
- BFRG Retail: Computer Software & Peripheral Equipment
- BIAF Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- BFRG Technology
- BIAF Health Care
- Exchange
- BFRG Nasdaq
- BIAF Nasdaq
- Market Cap
- BFRG 21.2M
- BIAF 21.4M
- IPO Year
- BFRG 2023
- BIAF 2022
- Fundamental
- Price
- BFRG $1.97
- BIAF $1.22
- Analyst Decision
- BFRG
- BIAF Strong Buy
- Analyst Count
- BFRG 0
- BIAF 1
- Target Price
- BFRG N/A
- BIAF $6.00
- AVG Volume (30 Days)
- BFRG 82.4K
- BIAF 102.5K
- Earning Date
- BFRG 11-08-2024
- BIAF 11-14-2024
- Dividend Yield
- BFRG N/A
- BIAF N/A
- EPS Growth
- BFRG N/A
- BIAF N/A
- EPS
- BFRG N/A
- BIAF N/A
- Revenue
- BFRG N/A
- BIAF $9,367,785.00
- Revenue This Year
- BFRG N/A
- BIAF $302.41
- Revenue Next Year
- BFRG N/A
- BIAF $15.00
- P/E Ratio
- BFRG N/A
- BIAF N/A
- Revenue Growth
- BFRG 550.00
- BIAF 2813.87
- 52 Week Low
- BFRG $1.43
- BIAF $1.20
- 52 Week High
- BFRG $8.35
- BIAF $3.62
- Technical
- Relative Strength Index (RSI)
- BFRG 31.66
- BIAF 35.89
- Support Level
- BFRG $2.05
- BIAF $1.21
- Resistance Level
- BFRG $2.68
- BIAF $1.37
- Average True Range (ATR)
- BFRG 0.20
- BIAF 0.08
- MACD
- BFRG -0.05
- BIAF 0.01
- Stochastic Oscillator
- BFRG 2.53
- BIAF 10.00
About BFRG Bullfrog AI Holdings Inc.
Bullfrog AI Holdings Inc is a clinical-phase Biotechnology company using machine learning to advance medicine and improve human health. It uses artificial intelligence and machine learning to advance medicines for both internal and external projects. Its platform technology, named, bfLEAP, is an analytical AI/ML platform that is able to surmount the challenges of scalability and flexibility currently hindering researchers and clinicians by providing a more precise1, multi-dimensional understanding of its data.
About BIAF bioAffinity Technologies Inc.
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.